What the DCCT showed, and what it cost
The 1983–1993 trial that proved managing glucose lowers the risk of complications, the 30-year follow-up, and the trade-off it came with.
Does the daily work of managing type 1 actually change what happens decades later? That question was settled in a randomised trial about forty years ago. This page explains what the trial found, what the 30-year follow-up added, and why the trade-off it came with looks very different today.
The trial
From 1983 to 1993, the Diabetes Control and Complications Trial (DCCT) followed 1,441 people with type 1 diabetes, split into two groups. One group got the standard care of the day. The other got intensive management: more injections, far more monitoring, constant adjustment.
It was a randomised trial, not an observation of people who happened to do things differently, and it is the reason the modern model of type 1 care exists.
After six and a half years, the difference between the two groups came down to one thing: an average A1C of about 7% against about 9%. That gap of two percentage points was the entire experiment. It is also the most important thing anyone with type 1 has ever been given: proof that the daily effort buys something real.
What those two points bought
Compared with conventional therapy, over a mean of 6.5 years, intensive management gave:
- 76% lower risk of developing eye disease
- 60% lower risk of nerve damage at five years
- 54% lower risk of protein leaking into the urine
- 53% lower risk of nerve damage affecting the heart
These are the largest effect sizes in the whole of diabetes medicine, and they came from managing glucose, nothing else. Note what they are: large reductions in risk. None of them abolishes the risk, and that honest distinction matters for everything that follows.
Thirty years of follow-up
When the trial ended, everyone was offered intensive management, and the two groups' A1C levels converged. A follow-up study called EDIC kept tracking them anyway. The gap that opened in those first six years never fully closed.
- 42% fewer cardiovascular events at about 17 years, and still 30% fewer at 30 years
- 57% fewer heart attacks, strokes and cardiac deaths
- 33% lower risk of dying over 27 years (this difference took about 15 years to show up)
- 65% of all participants still had no advanced eye disease at 30 years
That last figure is the one worth dwelling on. Two-thirds of the people in a 1980s cohort, using 1980s tools, reached thirty years without advanced eye disease.
Your body remembers the good stretches too
Researchers call this metabolic memory. A period of near-normal glucose keeps paying off for years afterwards, even if the numbers later rise again. In the four to eight years after the trial ended, when both groups had the same A1C, the original intensive group still had 72% less eye disease progression and 84% less new protein leakage from the kidneys.
Both halves matter. People who have had a hard stretch often conclude that their future is already fixed. The evidence says otherwise: it is never a case of "the damage is already done".
What the trial cost, and why your version is different
Stating that openly is what makes the rest of the numbers believable. But the people in the trial had no continuous glucose monitors, no alarms, no modern insulin analogues and no automated insulin delivery. Lower glucose and fewer severe lows are no longer opposing goals in the way they were then. Today's tools were built specifically to break that trade-off.
It is also worth remembering that every risk figure in these pages comes from people managing type 1 with the technology of decades ago.